FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-ra...
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
About this item
Full title
Author / Creator
Publisher
England: British Medical Journal Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
England: British Medical Journal Publishing Group
Subjects
More information
Scope and Contents
Contents
AbstractObjectiveTo analyze the US Food and Drug Administration (FDA) approval, trials, unmet needs, benefit, and pricing of ultra-rare (<6600 affected US citizens), rare (6600-200 000 citizens), and common (>200 000 citizens) orphan cancer drug indications and non-orphan cancer drug indications.DesignCross sectional analysis.SettingData from Drugs...
Alternative Titles
Full title
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2811941786
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2811941786
Other Identifiers
ISSN
1756-1833
E-ISSN
1756-1833
DOI
10.1136/bmj-2022-073242
